(DNTH)

Reporting relationship: SVP, General Counsel and Sec.
Issuer ticker: DNTH
Reported as of: 13 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 16:30:03 UTC
Prior SEC filing: 11 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Veness

Key filing fact

Adam M. Veness filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 14 Aug 2026.

Key facts

This page summarizes Adam M. Veness's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 16:30.

Change

Previous filing in this sequence was filed on 11 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001778623 Primary reporting owner

Veness Adam M

Relationship: SVP, General Counsel and Sec.
Address: C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
Signature: /s/ Adam Veness
Signature date: 14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Options Exercise

Transaction value
Shares: +15,000
Change %
Price: $18.17^*
Shares after: 15,000
Date: 13 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -15,000
Change %: -17%
Price: $0.000000^*
Shares after: 73,240
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $18.17
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.